Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
2000-02-22
2000-12-26
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 31205
Patent
active
061660779
ABSTRACT:
A method is provided for increasing the levels of IGF-1 for the therapeutic treatment or prophylaxis of cytological disorders or diseases related to IGF-1 selected from the group including neuropathies of the optic nerve and of the olfactory nerve, neuralgia of the trigmeninal nerve, Bell's paralysis, amyotrophic lateral sclerosis, osteoporosis, anthropathy, arthritis, cervical spondylosis and hernia of the intervertebral discs clinical syndromes of reduces height, cachexia and acute or chronic hepatic necrosis, Turner's syndrome, sarcopoenia, growth hormone insensitivity syndromes, obesity, asthenia, myasthenia and heart asthenia, immunodeficiencies and reperfusion injuries, and for the cicatrization of wounds, the healing of ulcers, the treatment of burns, tissue regeneration, cutaneous, intestinal and hepatic tissue regeneration and the formation of dentine, that includes administering, to a patient in need thereof, at least one selected from the group including L-acetylcarnitine, L-isovalerylcarnitine, and L-propionylcarnitine or pharmacologically acceptable salts thereof.
REFERENCES:
patent: 5227518 (1993-07-01), Cavazza
patent: 5240961 (1993-08-01), Shug
patent: 5656628 (1997-08-01), Weil et al.
patent: 6037373 (2000-03-01), De Simone
Walter G. Sannita et al, "Effects of intravenous L-acetylcarnitine on retinal oscillatory potentials", Documenta Ophthalmologica, vol. 70, 1988, pp. 89-96.
D.J. Paulson et al, "Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation", Cardiovascular Research, vol. 20, 1986, pp. 536-541.
A.J. Liedtke et al, "Effects of L-propionylcarnitine on mechanical recovery during reflow in intact hearts", AM. J. Physiol., vol. 255, No. 1, 1988, pp. H169-H176.
C. Adembri et al, "Ischemia-reperfusion of human skeletal muscle during aortoliliac surgery: effects of acetylcarnitine", Histol Histopath, vol. 9, 1994, pp. 683-690.
J.A. Leipala et al, "Protection of the reperfuse heart by L-propionylcarnitine", J. Applied Physiol., vol. 71, No. 4, 1991, pp. 1518-1528.
Luisa Di Marzio et al, "Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation", Clinical Immunology, vol. 92, No. 1, 1999, pp. 103-110.
Henley III Raymond
Mendes s.r.l.
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
LandOfFree
Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarn does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarn, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarn will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-995472